Streptomycin treatment alters the Intestinal Microbiome, Pulmonary T Cell profile and Airway Hyperresponsiveness in a Cystic Fibrosis Mouse Model

Mark Bazett Marie-Eve Bergeron and Christina K. Haston

Supporting Information



S1 Figure. Body weight of female BALB/c *Cftr*^{tm1UNC} mice and wild-type littermates, untreated or treated with streptomycin beginning *in utero* until death at 12 weeks of age. Average weight \pm standard deviation of n=6-10 mice per group. Weight did not significantly differ between untreated and Streptomycin treated mice for either of *Cftr*^{tm1UNC} or wild-type mice at any age (Student's *t*-test).



S2 Figure. Phylum level classification of intestinal microbiome from female BALB/c $Cftr^{tm1UNC}$ mice and wild-type littermates, untreated and treated with streptomycin beginning *in utero* until death at 12 weeks of age. * indicates a significant difference, P < 0.05 in bacterial abundance at the phylum level from untreated $Cftr^{tm1UNC}$ mice. There was no significance difference in bacterial abundance at the phylum level among untreated wild-type, streptomycin treated wild-type or streptomycin treated $Cftr^{tm1UNC}$ mice. The group "other" contains the phylum Tm7, Tenericutes, Acidobacteria, Planctomycetes and unclassified bacteria.



S3. Figure. Lymphocyte profiling of the lungs and mesenteric lymph nodes of female BALB/c *Cftr*^{tm1UNC} mice and wild-type littermates, untreated or treated with streptomycin beginning *in utero* until death at 12 weeks of age, as determined by flow cytometry. T lymphocyte subsets in the (A) lungs or (B) mesenteric lymph nodes. Average \pm standard deviation is shown (n=6-11 mice per group). * indicates a significant difference between groups, P < 0.05, by Student's *t*-test.

S4 Figure. Right lung cytokine gene expression of female BALB/c $Cftr^{tm1UNC}$ mice and wildtype littermates, untreated or treated with streptomycin beginning *in utero* until death at 12 weeks of age. Quantitative real-time PCR measures of expression presented as the average \pm standard deviation, relative to the reference gene Ataxin 10, of 4-9 mice per group. * indicates a significant difference between groups, P < 0.05, by Student's *t*-test. *Il-17A* expression was below detection for most samples.

S5. Figure. Leukocyte profiling of the lungs of female BALB/c Cftr^{tm1UNC} mice and wildtype littermates, untreated or treated with streptomycin beginning in utero until death at 12 weeks of age, as determined by flow cytometry. Alveolar macrophages, interstitial macrophages, eosinophils, neutrophils, and CD11b⁺ dendritic cells as a percent of lung CD45⁺ macrophages; DC dendritic, cells. Mphage dendritic cells. CD11b+ == CD45⁺CD11c⁺CD11b⁺CD24⁺CD64⁻MHC class II⁺; alveolar macrophages CD45⁺CD11c⁺CD11b⁻ CD64⁺CD24⁻; interstitial macrophages, CD45⁺CD11c⁺CD11b⁺CD24⁻CD64⁺MHC class II⁺; eosinophils, CD45⁺CD11b⁺MHC class II⁻CD24⁺Siglec F⁺; and neutrophils, CD45⁺CD11b⁺MHC class II⁻CD24⁺Siglec F⁻. Average \pm standard deviation is shown (n=8-14 mice per group). * indicates a significant difference between groups, P < 0.05, by Student's *t*-test.

S6. Figure. Gating strategies for lymphocyte and leukocyte profiling. A) Sample gating strategy depicted with a wild-type untreated mouse with fluorescent minus one (FMOs) controls shown for IL-17, IFN γ and IL-13. B) Gating strategy for leukocyte profiling depicted with a wild-type untreated mouse. Macrophages and dendritic cells (DCs) were also selected for CD11c+ staining (not shown).